ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RARE vs NUVB // ALTMAN Z-SCORE & DEBT/EQUITY

Ultragenyx Pharmaceutical Inc. (NASDAQ) VS. Nuvation Bio Inc. (Class A) (NYSE) • 15-METRIC TALLY: RARE 1 — NUVB 4
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: NUVB
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RARE VS. NUVB) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RARE NUVB SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -10.35% — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 20.20% 180.00% -159.80 NUVB /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE 0.20 0.76 -0.56 NUVB /balance-sheet <GO>
Piotroski F-Score Quality 3/9 4/9 -1.00 NUVB /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 49.8 42.2 +7.58 RARE /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.65B $1.67B -$20.5M NUVB /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RARE REV NUVB REV RARE GROSS % NUVB GROSS % RARE FCF NUVB FCF
FY 2025 $673.0M $62.9M — — -$472.0M -$173.4M
FY 2024 $560.0M $7.9M — 10.1% -$421.0M -$130.4M
FY 2023 $434.0M $0 — — -$475.0M -$68.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RARE // BETA —
NUVB // BETA —